Literature DB >> 27099149

Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome.

Simon Völkl1, Anne Rensing-Ehl2, Andrea Allgäuer1, Elisabeth Schreiner1, Myriam Ricarda Lorenz3, Jan Rohr4, Christian Klemann4, Ilka Fuchs2, Volker Schuster5, André O von Bueren6, Nora Naumann-Bartsch7, Eleonora Gambineri8, Kathrin Siepermann9, Robin Kobbe10, Michaela Nathrath11, Peter D Arkwright12, Maurizio Miano13, Klaus-Daniel Stachel7, Markus Metzler7, Klaus Schwarz14, Anita N Kremer1, Carsten Speckmann15, Stephan Ehl15, Andreas Mackensen1.   

Abstract

Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder characterized by defective Fas signaling, resulting in chronic benign lymphoproliferation and accumulation of TCRαβ(+) CD4(-) CD8(-) double-negative T (DNT) cells. Although their phenotype resembles that of terminally differentiated or exhausted T cells, lack of KLRG1, high eomesodermin, and marginal T-bet expression point instead to a long-lived memory state with potent proliferative capacity. Here we show that despite their terminally differentiated phenotype, human ALPS DNT cells exhibit substantial mitotic activity in vivo. Notably, hyperproliferation of ALPS DNT cells is associated with increased basal and activation-induced phosphorylation of serine-threonine kinases Akt and mechanistic target of rapamycin (mTOR). The mTOR inhibitor rapamycin abrogated survival and proliferation of ALPS DNT cells, but not of CD4(+) or CD8(+) T cells in vitro. In vivo, mTOR inhibition reduced proliferation and abnormal differentiation by DNT cells. Importantly, increased mitotic activity and hyperactive mTOR signaling was also observed in recently defined CD4(+) or CD8(+) precursor DNT cells, and mTOR inhibition specifically reduced these cells in vivo, indicating abnormal programming of Fas-deficient T cells before the DNT stage. Thus, our results identify the mTOR pathway as a major regulator of lymphoproliferation and aberrant differentiation in ALPS.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27099149     DOI: 10.1182/blood-2015-11-685024

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.

Authors:  Christian Klemann; Myrian Esquivel; Aude Magerus-Chatinet; Myriam R Lorenz; Ilka Fuchs; Nathalie Neveux; Martin Castelle; Jan Rohr; Claudia Bettoni da Cunha; Martin Ebinger; Robin Kobbe; Bernhard Kremens; Florian Kollert; Eleonora Gambineri; Kai Lehmberg; Markus G Seidel; Kathrin Siepermann; Thomas Voelker; Volker Schuster; Sigune Goldacker; Klaus Schwarz; Carsten Speckmann; Capucine Picard; Alain Fischer; Frederic Rieux-Laucat; Stephan Ehl; Anne Rensing-Ehl; Benedicte Neven
Journal:  Haematologica       Date:  2016-10-27       Impact factor: 9.941

2.  Lymphoproliferation, immunodeficiency and early-onset inflammatory bowel disease associated with a novel mutation in Caspase 8.

Authors:  Veronika Kanderova; Hana Grombirikova; Irena Zentsova; Kamila Reblova; Adam Klocperk; Martina Fejtkova; Marketa Bloomfield; Barbora Ravcukova; Tomas Kalina; Tomas Freiberger; Anna Sediva
Journal:  Haematologica       Date:  2018-10-18       Impact factor: 9.941

3.  Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome.

Authors:  Stefano Vavassori; Jacob D Galson; Johannes Trück; Anke van den Berg; Rienk Y J Tamminga; Aude Magerus-Chatinet; Olivier Pellé; Ulrike Camenisch Gross; Ewerton Marques Maggio; Seraina Prader; Lennart Opitz; Ursina Nüesch; Andrea Mauracher; Benjamin Volkmer; Oliver Speer; Luzia Suda; Benno Röthlisberger; Dieter Robert Zimmermann; Rouven Müller; Arjan Diepstra; Lydia Visser; Eugenia Haralambieva; Bénédicte Neven; Frédéric Rieux-Laucat; Jana Pachlopnik Schmid
Journal:  Blood Adv       Date:  2017-06-22

4.  Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.

Authors:  F Fioredda; E Cappelli; A Mariani; A Beccaria; E Palmisani; A Grossi; I Ceccherini; R Venè; C Micalizzi; M Calvillo; F Pierri; I Mancini; F Peyvandi; F Corsolini; C Dufour; M Miano
Journal:  Blood Adv       Date:  2019-11-12

5.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 6.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

7.  Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5.

Authors:  Dita Gratzinger; Elaine S Jaffe; Amy Chadburn; John K C Chan; Daphne de Jong; John R Goodlad; Jonathan Said; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 8.  Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.

Authors:  Karen Bride; David Teachey
Journal:  F1000Res       Date:  2017-11-01

Review 9.  Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance.

Authors:  Akiko Yamada; Rieko Arakaki; Masako Saito; Yasusei Kudo; Naozumi Ishimaru
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

10.  Autoimmune Lymphoproliferative Syndrome-FAS Patients Have an Abnormal Regulatory T Cell (Treg) Phenotype but Display Normal Natural Treg-Suppressive Function on T Cell Proliferation.

Authors:  Fabienne Mazerolles; Marie-Claude Stolzenberg; Olivier Pelle; Capucine Picard; Benedicte Neven; Alain Fischer; Aude Magerus-Chatinet; Frederic Rieux-Laucat
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.